NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 29.6% in December

NextCure, Inc. (NASDAQ:NXTC) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 26,706 shares, an increase of 29.6% from the November 30th total of 20,613 shares. Based on an average trading volume of 45,355 shares, the short-interest ratio is currently 0.6 days. Currently, 1.1% of the company’s shares are sold short. Currently, 1.1% of the company’s shares are sold short. Based on an average trading volume of 45,355 shares, the short-interest ratio is currently 0.6 days.

NextCure Trading Up 5.8%

NextCure stock opened at $13.98 on Wednesday. The firm has a market capitalization of $49.07 million, a price-to-earnings ratio of -0.58 and a beta of 1.54. The firm’s fifty day moving average price is $11.27 and its two-hundred day moving average price is $7.62. NextCure has a 1-year low of $2.69 and a 1-year high of $15.74.

NextCure (NASDAQ:NXTC) last posted its earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. On average, research analysts forecast that NextCure will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP lifted its holdings in shares of NextCure, Inc. (NASDAQ:NXTC) by 13.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 at the end of the most recent reporting period. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. LADENBURG THALM/SH SH raised shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, November 7th. Finally, Wall Street Zen raised shares of NextCure to a “hold” rating in a research note on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.